Stryker Co. (NYSE:SYK) Shares Sold by Ieq Capital LLC

Ieq Capital LLC decreased its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 35.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,687 shares of the medical technology company's stock after selling 11,805 shares during the period. Ieq Capital LLC's holdings in Stryker were worth $7,808,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Opal Wealth Advisors LLC boosted its holdings in shares of Stryker by 1.6% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after buying an additional 28 shares during the last quarter. Alhambra Investment Management LLC lifted its stake in Stryker by 1.5% during the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock worth $719,000 after purchasing an additional 29 shares during the last quarter. JFS Wealth Advisors LLC boosted its stake in shares of Stryker by 4.4% in the 4th quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock valued at $247,000 after purchasing an additional 29 shares in the last quarter. Capital & Planning LLC boosted its holdings in Stryker by 3.6% during the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock valued at $304,000 after acquiring an additional 29 shares during the period. Finally, Concord Wealth Partners boosted its position in Stryker by 2.2% during the 4th quarter. Concord Wealth Partners now owns 1,396 shares of the medical technology company's stock valued at $503,000 after buying an additional 30 shares during the period. 77.09% of the stock is owned by institutional investors.

Stryker Stock Down 1.0 %

Shares of SYK stock traded down $3.82 during mid-day trading on Friday, hitting $382.59. The stock had a trading volume of 1,268,413 shares, compared to its average volume of 1,388,856. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market capitalization of $145.99 billion, a P/E ratio of 49.30, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The firm's 50-day moving average is $377.92 and its two-hundred day moving average is $368.21.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company earned $3.46 EPS. On average, analysts predict that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio is currently 43.30%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on SYK shares. Wells Fargo & Company raised their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. JMP Securities restated a "market perform" rating on shares of Stryker in a report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Needham & Company LLC reaffirmed a "buy" rating and issued a $442.00 target price on shares of Stryker in a report on Wednesday, January 29th. Finally, Canaccord Genuity Group raised their price objective on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $420.68.

Insider Activity

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.